According to the 5th edition of the WHO guidelines, BPDCN is defined by immuno-positivity for three core biomarkers, CD123, CD4 and CD56, in addition to one of the following: TCF4, TCL1, CD303, and CD304. This evidence concerns the gene NRP1 and CD4+/CD56+ hematodermic neoplasm.